RLAY
VENTE TOTALE: 96 398 titres (~1 892 774,73 $ US)
- Insiders
- Patel Sanjiv
- Total bought
- —
- Total sold
- $1,892,775
- Last activity
- 2026-09-08
- Last synced
-
2026-09-11 10:16:43
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-11
RLAY presents a structurally weak profile: despite solid liquidity (score 85), the near-absent catalyst score (20) driven by significant insider selling from both the CEO and CFO signals a lack of internal conviction in…
The first sentence of the analysis written for RLAY on 2026-09-11 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 76.8% | -3052.2% | -1177.6% | -17496.3% | -5492.2% | |
| Ebit Margin | -1800.6% | -3854.0% | -1485.3% | -22516.4% | -7494.5% | |
| Ebitda Margin | -1777.4% | -3799.4% | -1464.6% | -22217.4% | -7364.9% | |
| Operating Profit Margin | -1971.6% | -3722.1% | -1460.1% | -21670.9% | -12040.2% | |
| Pretax Profit Margin | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | |
| Continuous Operations Profit Margin | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | |
| Net Profit Margin | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | |
| Bottom Line Profit Margin | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | |
| Current Ratio | 22.608 | 15.952 | 25.442 | 16.003 | 40.140 | |
| Quick Ratio | 22.608 | 15.952 | 25.442 | 15.812 | 40.140 | |
| Solvency Ratio | -5.029 | -3.553 | -3.661 | -1.915 | -3.253 | |
| Cash Ratio | 3.285 | 2.450 | 4.749 | 2.383 | 11.518 | |
| Price To Earnings Ratio | -5.255 | -1.746 | -3.946 | -5.768 | -8.039 | |
| Price To Earnings Growth Ratio | 0.165 | 0.113 | -0.511 | 0.179 | -0.163 | |
| Forward Price To Earnings Growth Ratio | 0.165 | 0.113 | -0.511 | 0.179 | -0.163 | |
| Price To Earnings Diluted Ratio | -5.255 | -1.746 | -3.946 | -5.768 | -8.039 | |
| Price To Earnings Diluted Growth Ratio | 0.165 | 0.113 | -0.511 | 0.179 | -0.163 | |
| Price To Book Ratio | 2.560 | 0.757 | 1.795 | 1.765 | 3.254 | |
| Price To Sales Ratio | 94.537 | 58.820 | 52.829 | 1,214.171 | 964.559 | |
| Price To Free Cash Flow Ratio | -6.154 | -2.344 | -4.433 | -7.029 | -37.516 | |
| Price To Operating Cash Flow Ratio | -6.165 | -2.363 | -4.494 | -7.307 | -39.266 | |
| Debt To Assets Ratio | 0.052 | 0.056 | 0.063 | 0.053 | 0.023 | |
| Debt To Equity Ratio | 0.057 | 0.062 | 0.071 | 0.061 | 0.026 | |
| Debt To Capital Ratio | 0.054 | 0.059 | 0.066 | 0.057 | 0.025 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.096 | 1.120 | 1.122 | 1.157 | 1.123 | |
| Working Capital Turnover Ratio | 0.023 | 0.013 | 0.030 | 0.001 | 0.004 | |
| Operating Cash Flow Ratio | -9.205 | -4.911 | -9.922 | -3.602 | -3.059 | |
| Operating Cash Flow Sales Ratio | -15.334 | -24.893 | -11.756 | -166.177 | -24.565 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.008 | 1.014 | 1.039 | 1.047 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -7.254 | -5.136 | -5.617 | -3.974 | -3.249 | |
| Capital Expenditure Coverage Ratio | -574.280 | -123.443 | -72.786 | -25.324 | -21.436 | |
| Dividend Paid And Capex Coverage Ratio | -574.280 | -123.443 | -72.786 | -25.324 | -21.436 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.130 | -1.349 | -3.366 | -5.158 | -11.944 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 76.8% | ▲3129.0% | ▲5505.1% |
| Ebit Margin | -1800.6% | ▲2053.5% | ▲5629.6% |
| Ebitda Margin | -1777.4% | ▲2022.0% | ▲5547.3% |
| Operating Profit Margin | -1971.6% | ▲1750.5% | ▲6201.4% |
| Pretax Profit Margin | -1800.6% | ▲1574.1% | ▲6112.0% |
| Continuous Operations Profit Margin | -1800.6% | ▲1574.1% | ▲6112.0% |
| Net Profit Margin | -1800.6% | ▲1574.1% | ▲6112.0% |
| Bottom Line Profit Margin | -1800.6% | ▲1574.1% | ▲6112.0% |
| Current Ratio | 22.608 | ▲6.657 | ▼-1.420 |
| Quick Ratio | 22.608 | ▲6.657 | ▼-1.382 |
| Solvency Ratio | -5.029 | ▼-1.476 | ▼-1.547 |
| Cash Ratio | 3.285 | ▲0.835 | ▼-1.592 |
| Price To Earnings Ratio | -5.255 | ▼-3.509 | ▼-0.304 |
| Price To Earnings Growth Ratio | 0.165 | ▲0.052 | ▲0.209 |
| Forward Price To Earnings Growth Ratio | 0.165 | ▲0.052 | ▲0.209 |
| Price To Earnings Diluted Ratio | -5.255 | ▼-3.509 | ▼-0.304 |
| Price To Earnings Diluted Growth Ratio | 0.165 | ▲0.052 | ▲0.209 |
| Price To Book Ratio | 2.560 | ▲1.803 | ▲0.534 |
| Price To Sales Ratio | 94.537 | ▲35.717 | ▼-382.446 |
| Price To Free Cash Flow Ratio | -6.154 | ▼-3.811 | ▲5.341 |
| Price To Operating Cash Flow Ratio | -6.165 | ▼-3.802 | ▲5.754 |
| Debt To Assets Ratio | 0.052 | ▼-0.003 | ▲0.003 |
| Debt To Equity Ratio | 0.057 | ▼-0.005 | ▲0.002 |
| Debt To Capital Ratio | 0.054 | ▼-0.005 | ▲0.002 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.096 | ▼-0.025 | ▼-0.028 |
| Working Capital Turnover Ratio | 0.023 | ▲0.010 | ▲0.009 |
| Operating Cash Flow Ratio | -9.205 | ▼-4.295 | ▼-3.066 |
| Operating Cash Flow Sales Ratio | -15.334 | ▲9.559 | ▲33.211 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▼-0.006 | ▼-0.020 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -7.254 | ▼-2.118 | ▼-2.208 |
| Capital Expenditure Coverage Ratio | -574.280 | ▼-450.838 | ▼-410.827 |
| Dividend Paid And Capex Coverage Ratio | -574.280 | ▼-450.838 | ▼-410.827 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.130 | ▼-3.781 | ▲0.259 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.45B | $588.6M | $1.35B | $1.68B | $2.92B | |
| Enterprise value | $1.40B | $512.8M | $1.26B | $1.58B | $2.66B | |
| EV / Sales | 91.18x | 51.25x | 49.30x | 1146.07x | 879.64x | |
| EV / Op. cash flow | -5.95x | -2.06x | -4.19x | -6.90x | -35.81x | |
| EV / Free cash flow | -5.94x | -2.04x | -4.14x | -6.63x | -34.21x | |
| EV / EBITDA | -5.13x | -1.35x | -3.37x | -5.16x | -11.94x | |
| Net debt / EBITDA | 0.19x | 0.20x | 0.24x | 0.31x | 1.15x | |
| Current ratio | 22.61x | 15.95x | 25.44x | 16.00x | 40.14x | |
| Income quality | 0.85x | 0.74x | 0.88x | 0.79x | 0.20x | |
| Graham net-net | $3 | $5 | $5 | $8 | $9 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 87.6% | 90.1% | 93.4% | 160.3% | |
| Working capital | $552.7M | $758.5M | $739.8M | $955.8M | $951.9M | |
| Invested capital | $594.4M | $818.4M | $811.0M | $1.03B | $981.5M | |
| Return on assets | -44.5% | -38.8% | -40.5% | -26.4% | -36.1% | |
| Operating ROA | -40.6% | -43.4% | -38.4% | -28.4% | -40.3% | |
| Return on tangible assets | -44.5% | -38.9% | -40.6% | -26.5% | -36.2% | |
| Return on equity | -48.8% | -43.4% | -45.5% | -30.6% | -40.5% | |
| Return on invested capital | -50.5% | -45.1% | -45.6% | -28.8% | -37.0% | |
| Return on capital employed | -50.8% | -45.4% | -45.8% | -28.9% | -37.1% | |
| Earnings yield | -19.0% | -57.4% | -25.3% | -17.3% | -12.5% | |
| Free cash flow yield | -16.2% | -42.7% | -22.6% | -14.2% | -2.7% | |
| Capex / Op. cash flow | -0.2% | -0.8% | -1.4% | -3.9% | -4.7% | |
| Capex / Depreciation | -29.5% | 36.9% | 78.3% | 219.4% | 88.4% | |
| Capex / Sales | 2.7% | 20.2% | 16.2% | 656.2% | 114.6% | |
| SG&A / Sales | 369.3% | 801.8% | 307.6% | 5020.1% | 1972.5% | |
| R&D / Sales | 1702.3% | 3188.7% | 1291.9% | 17838.9% | 9760.6% | |
| Stock comp / Sales | 406.5% | 940.7% | 336.8% | 4065.0% | 1599.7% | |
| Intangibles / Total assets | 0.0% | 0.3% | 0.3% | 0.2% | 0.2% | |
| Days sales outstanding | 0d | 0d | 0d | 1379d | 595d | |
| Days payables outstanding | 791d | 16d | 10d | 16d | 18d | |
| Operating cycle | 0d | 0d | 0d | 1398d | 595d | |
| Cash conversion cycle | -791d | -16d | -10d | 1382d | 577d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+146.6%EV / Sales ▲+77.9%EV / EBITDA ▼-280.3%EV / Op. cash flow ▼-3.888Earnings yield ▲+0.383
Profitability
Return on equity ▼-0.053Return on assets ▼-0.057Return on invested capital ▼-0.054Return on capital employed ▼-0.054Operating ROA ▲+0.029Income quality ▲+0.114Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+774.333Operating cycle n/aCash conversion cycle ▼-774.333Capex / Sales ▼-0.175R&D / Sales ▼-14.864
Balance-sheet strength
Current ratio ▲+6.657Net debt / EBITDA ▼-0.010Working capital ▼-205774000.000Invested capital ▼-224031000.000Intangibles / Total assets ▼-0.003
Change over 5 years
Valuation
Market cap ▼-50.3%EV / Sales ▼-89.6%EV / EBITDA ▲+57.0%EV / Op. cash flow ▲+29.863Earnings yield ▼-0.066
Profitability
Return on equity ▼-0.082Return on assets ▼-0.084Return on invested capital ▼-0.135Return on capital employed ▼-0.138Operating ROA ▼-0.002Income quality ▲+0.647Tax burden 0.000
Efficiency
Days sales outstanding ▼-595.279Days payables outstanding ▲+772.812Operating cycle ▼-595.279Cash conversion cycle ▼-1368.091Capex / Sales ▼-1.119R&D / Sales ▼-80.584
Balance-sheet strength
Current ratio ▼-17.531Net debt / EBITDA ▼-0.964Working capital ▼-399220000.000Invested capital ▼-387127000.000Intangibles / Total assets ▼-0.002
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-07-11 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
Recent news
- 2026-09-10 Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
- 2026-09-10 Allianz Asset Management GmbH Makes New $750,000 Investment in Relay Therapeutics, Inc. $RLAY Allianz Asset Management GmbH acquired a new stake in Relay Therapeutics, Inc. (NASDAQ: RLAY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 40,100 shares of the company''s stock, valued at approximately $750,000. Other large investors have also recently made changes
- 2026-09-07 Frazier Life Sciences Management L.P. Takes $19 Million Position in Relay Therapeutics, Inc. $RLAY Frazier Life Sciences Management L.P. acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,015,693 shares of the company''s stock, valued at approximately $19,004,000. Frazier Life Sciences
- 2026-09-02 Relay Therapeutics CFO Sells 17,717 Shares for $350,000 The sale had an approximate value of nearly $350,000. The transaction reduced the executive''s direct equity position by 11%.
- 2026-09-01 Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
- 2026-08-20 Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE Bank of America Corp DE raised its stake in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 86.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,937,695 shares of the company''s stock after purchasing an additional 896,746 shares during the
- 2026-08-17 4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
- 2026-08-06 Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.
- 2026-08-06 Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates Selected z ovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine - sensitive patients expected to initiate in early 2027, subject to regulatory feedback
- 2026-07-30 Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026 CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report second quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 6, 2026.